The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
The proposed transaction will be effected as a share swap
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Both organisations enter into a long- term collaboration to expand patient access in India
Total transaction value of the divestment is Rs. 3,660 million
_256_384.jpg)
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
Subscribe To Our Newsletter & Stay Updated
